From single to dual platelet inhibition FIBTEM assay: fibrinogen replacement thresholds for critical bleeding after trauma
Akmez Latona, James Winearls, Alan Ho, Biswadev Mitra · 2026
Read From single to dual platelet inhibition FIBTEM assay: fibrinogen replacement thresholds for critical bleeding after trauma by Akmez Latona, James Winearls, Alan Ho, Biswadev Mitra (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13279660.txt.
Description
Akmez Latona and colleagues report a 2026 study of a blood clot test change in major trauma care. The FIBTEM test, part of a clot check called ROTEM, weighs fibrin based clot build. Fibrin is the mesh protein in clots. Its reagent changed from one platelet blocker to two, for fuller platelet shut down. Platelets are small blood cells that plug wounds. The team ask if the change shifts transfusion trigger points.
Adult major trauma patients across Queensland from 2022 to 2025 gave paired clot test and standard lab results on arrival. The link between the FIBTEM early clot size and lab fibrinogen was alike for old and new reagents. Forecast clot sizes at the key fibrinogen mark were near the same, about eight and about seven and a half millimetres. Test power to spot low fibrinogen was checked as well. Trigger points can stay put across the reagent change.
Catalog record
| CREATOR | Akmez Latona, James Winearls, Alan Ho, Biswadev Mitra |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 29437 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |